Sprout Health Review: What Its GLP-1 Documentation Establishes—and What It Does Not

A published price is evidence of an advertised offer, not evidence of a treatment outcome. That distinction matters at Sprout Health, which markets compounded semaglutide and tirzepatide through a telehealth coordination model. Its public documentation gives prospective patients concrete information about prices, prescribing review, pharmacy handoffs and cancellation boundaries. It does not establish how well Sprout’s particular preparations work, identify their complete formulations or resolve several conflicting descriptions of the service.

This review examines public pages consulted October 19, 2026; those pages were not necessarily updated that day. The most useful reading separates current storefront claims, expressly older process instructions and contractual policies rather than blending them into one seamless service description. Sprout offers enough detail to support a substantive comparison, but some consequential questions remain open. In particular, clinical research on a named ingredient cannot fill gaps in documentation about the product, pharmacy or follow-up a patient would actually receive.

At a glance

Documented service model: Sprout coordinates care; it says a licensed clinician makes prescribing decisions and a state-licensed pharmacy prepares prescriptions. Sprout is not a pharmacy or drug manufacturer.
Sources: [4]
Compounded semaglutide pricing: $149 every four weeks, or a 12-month plan advertised as $99 per month with $1,188 paid upfront. The offer says any dose costs the same and includes the provider visit, medication and shipping.
Sources: [6]
Compounded tirzepatide pricing: $199 every four weeks, or a 12-month plan advertised as $149 per month and billed $1,788 upfront every 12 months.
Sources: [6]
Regulatory distinction: Sprout states that its compounded semaglutide and tirzepatide are not FDA approved, have not undergone FDA evaluation for safety, effectiveness or quality, and are not brand-name drugs or generics.
Sources: [6]
Cancellation deadline: The refund policy requires cancellation requests at least 48 hours before the next scheduled billing date to avoid that charge; later requests take effect the following cycle.
Sources: [8]

Start with the product evidence, not the ingredient name

Sprout explicitly offers compounded semaglutide and compounded tirzepatide, rather than presenting them as approved brand-name products or generics. Its disclosure that these preparations are not FDA approved is important, but incomplete as a product description. The consulted documentation does not specify their administration routes, full formulations or presentations. It also does not establish which pharmacy prepares each product. Those omissions limit how precisely a reader can connect the advertised offer to published clinical evidence.

FDA explains that compounded preparations do not undergo its premarket review for safety, effectiveness and quality. It recommends compounded drugs for patients whose medical needs cannot be met by an FDA-approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone neither proves clinical inequivalence nor validates the provider. Our guide to approved medicines and compounded preparations explains why product approval and the quality of an individual service are separate questions.

Sprout also advertises prescription-only compounded NAD+, identifying it as nicotinamide adenine dinucleotide. Its starting price is $199, but that block does not establish a supply period or commitment. Sprout says NAD+ is not FDA approved and would be prescribed according to individual needs. It is a separate documented offering, not evidence that Sprout’s GLP-1 preparations produce particular outcomes or that the products should be evaluated as one interchangeable treatment package.

Sources: [6] [1]

What published research can—and cannot—add

STEP 1 and SURMOUNT-1 are relevant research on semaglutide and tirzepatide, respectively, but neither is a study of Sprout Health. Both examined specified subcutaneous treatment regimens in adults with obesity or overweight and associated health conditions, without diabetes. Their populations, formulations, routes and follow-up conditions matter. An ingredient name on a storefront does not establish that the preparation offered there has been tested under the same conditions.

This is especially consequential when the provider’s route and full formulation remain unspecified. Trial findings do not establish results for Sprout’s compounded preparations, other routes, microdoses or an individual patient. Nor should results from separate trials become a head-to-head ranking. The distinction explained in why a clinical trial is not a telehealth performance report is the central evidence boundary here: research can inform a clinical conversation without measuring this company’s performance.

Sources: [2] [3]

Who reviews the patient—and who coordinates the service

The terms identify the business as Sprout Health Partners LLC and describe collaboration with MD Integrations, or MDI, a physician-only clinical network. Elsewhere, Sprout describes a licensed clinician reviewing health history and making every prescribing decision. Sprout’s own role is coordination, not pharmacy operation or drug manufacturing. These are useful responsibility statements, although the consulted documentation does not independently verify individual professional licenses or identify a prospective patient’s assigned clinician.

The advertised entry point is a short online assessment about health history and goals, followed by review by a state-licensed medical provider. Site use and registration are limited to adults 18 and older. A consultation does not guarantee treatment: the terms allow clinicians to decline or modify a requested plan. The public documentation does not provide complete clinical eligibility criteria, laboratory requirements or provider-specific BMI thresholds, so a successful initial screen should not be treated as a prescription.

An expressly older process guide describes a preliminary quiz that only prequalifies someone to purchase, followed by a more detailed medical questionnaire. It says an order is canceled and refunded if the clinician finds the patient unqualified. That sequence should not automatically be assigned to current accounts. The contact page distinguishes orders from July 2026 onward, managed through a patient account, from earlier orders handled in a Customer Portal—evidence that the service has different account pathways.

Sources: [9] [4] [6] [5] [10]

Prices are concrete; the billing calendar is less consistent

Sprout’s storefront publishes actual prices, not merely a request to contact sales. Compounded semaglutide is $149 every four weeks; the alternative 12-month plan is advertised as $99 per month with $1,188 collected upfront. Compounded tirzepatide is $199 every four weeks, or $149 per month under a 12-month plan billed $1,788 upfront every 12 months. These are alternative payment structures, not a requirement that everyone prepay annually.

The semaglutide offer says the price is the same at any dose and includes the provider visit, medication and shipping. The terms separately say checkout prices include the mandatory doctor consultation. However, the refund policy describes monthly, three-month and six-month subscriptions with automatic monthly charges, unlike the storefront’s four-week and annual options. Four weeks is not a calendar month. The annual plan label also does not establish shipment quantities or the supply calendar.

The table keeps those distinctions visible rather than converting every offer into a supposedly comparable monthly bill. Insurance acceptance, insurer reimbursement and HSA/FSA use are not clarified in the consulted documentation. Neither is the administration route or presentation attached to these prices. Before paying, the useful evidence is the specific checkout disclosure showing the product, amount collected now, renewal date, included services and policy applicable to that account.

Published offers and the conditions that change their meaning
Offer	Published charge	Important condition
Compounded semaglutide	$149 every four weeks	Renews until canceled; advertised visit, medication and shipping included; same price at any dose.
Compounded semaglutide, 12-month plan	$99/month equivalent; $1,188 upfront	An alternative prepaid plan, not a monthly installment offer.
Compounded tirzepatide	$199 every four weeks	Four-week billing is distinct from calendar-month billing.
Compounded tirzepatide, 12-month plan	$149/month equivalent; $1,788 upfront every 12 months	The advertised monthly equivalent requires the annual plan.
Compounded NAD+	Starting at $199	The price block does not specify supply duration or commitment.

Sources: [6] [8] [9]

Pharmacy handoffs and follow-up need separate scrutiny

Sprout says approved medication is filled by a partner pharmacy unless the patient specifies another licensed pharmacy. The terms list Foothills Pharmacy and Promise Pharmacy as external contacts, without allocating specific products to either. The homepage describes preparation by state-licensed U.S. pharmacies and discreet home delivery; these are provider statements, not independently verified credentials. The option to name another pharmacy also does not explain whether the advertised bundle or price remains unchanged.

The homepage says most prescriptions are sent to the pharmacy within two business days after completion of the visit. That is a prescribing handoff, not a delivery promise. The older guide separately describes typical dispatch within three to seven business days after a prescription is issued and sent to a partner pharmacy. It promises tracking by email and in the Customer Portal after shipment. Those stages cannot be combined into a guaranteed arrival date.

For renewals, the older guide describes a new questionnaire after each rebill to assess progress and possible side effects; another shipment depends on submission and an approved prescription. Current contact instructions direct medical questions to the clinician through the patient account or medical portal and say administrative support cannot give medical advice. No clinical response-time guarantee is established. As our clinical follow-up guide explains, a renewal mechanism documents a process, not the depth or timeliness of clinical care.

Sources: [9] [6] [5] [10]

Cancellation and refunds turn on different events

Sprout’s refund policy offers a full refund if cancellation or withdrawal occurs before the prescription is sent to the pharmacy, including after provider review. Once the prescription has been sent for fulfillment, it calls the order nonrefundable because clinical and pharmacy resources have been committed. That boundary can occur before dispatch or arrival. Sprout also states that it does not accept prescription-medication returns, so possession of unused medication does not create a return right.

For prepaid plans canceled early, the policy describes dividing the actual amount paid, including discounts, by the plan’s number of months, then refunding that value for months of medication not yet shipped. This deserves clarification alongside the general pharmacy-handoff cutoff rather than an assumption that either provision overrides the other. The consulted documentation does not fully reconcile how those rules apply to an annual plan’s individual prescriptions and shipments.

Avoiding the next charge requires a cancellation request received at least 48 hours before the scheduled billing date; later requests apply the following cycle. A shipment-delay request has a different deadline: at least five business days before scheduled dispatch to guarantee action, through email or the portal. During shortages, the stated standard practice is to wait for stock and fulfill the order rather than refund it. Canceling future renewals therefore is not synonymous with refunding an existing charge.

Sources: [8]

Delivery complaints have short, unevenly described deadlines

The refund policy requires notice within 24 hours of delivery for concerns about contents, condition or temperature integrity. It describes a no-cost replacement when damage or defect on arrival is confirmed. Packages marked delivered but not received have a separate 48-hour reporting window, with replacement reviewed individually rather than automatic. Another passage discusses requests after 48 hours and reshipments outside 72 hours, without clearly reconciling those references. The discrepancy is a reason to report promptly, not to assume the longest window governs.

For injectable GLP-1 medication arriving warm or inadequately refrigerated, FDA explicitly advises not using it and contacting the provider or dispensing pharmacy. This is distinct from whether Sprout approves a replacement claim. Its documentation does not independently establish transport stability for a particular preparation. Readers can use our guide to cold-chain and delivery claims to distinguish a shipping assertion from evidence that a specific package remained within appropriate conditions.

Sources: [8] [1]

State coverage and privacy remain unresolved

The terms exclude Alabama, Arkansas, Mississippi, Louisiana, California and North Dakota, while the privacy policy says services are available in all 50 states. The terms also list 15 states for synchronous MDI visits, including Arkansas despite its exclusion elsewhere. These statements do not establish nationwide access or a reliable state-by-state treatment map. Confirmation should cover the patient’s state, requested product and consultation format, rather than relying on a broad availability sentence.

Privacy language is similarly inconsistent. The terms say the site is not designed to comply with HIPAA and other industry-specific rules, whereas the older process guide calls the company fully HIPAA compliant. The privacy policy distinguishes authenticated interactions within an established patient relationship as governed by a HIPAA notice. That notice was not available in the consulted texts. These statements may concern different settings, but the documentation does not support an independent compliance conclusion.

The homepage footer also describes operational and marketing uses of information, potentially including hashed or de-identified data for advertising audiences on Google, Meta and similar platforms. Readers should clarify which information is collected before and after entering the care portal. For administrative questions, Sprout publishes help@joinsprouthealth.com and +1 (833) 496-4020, Monday through Friday, 9 a.m.–5:30 p.m. Mountain Time. Those contact hours do not establish a guaranteed response time or after-hours clinical availability.

Sources: [9] [7] [5] [6] [10]

Questions & answers

Does completing Sprout’s assessment guarantee a prescription?

No. Sprout says a licensed clinician determines whether treatment is appropriate, and its terms allow treatment to be declined or modified. The older guide distinguishes purchase prequalification from the later medical review and describes a refund for patients found unqualified. Because that guide is labeled older, current applicants should confirm the sequence and applicable refund terms before paying.

Sources: [6] [9] [5]

Is Sprout’s $99 semaglutide offer a monthly payment plan?

Not as advertised. It is a monthly equivalent attached to a 12-month plan with $1,188 paid upfront. The alternative published charge is $149 every four weeks. Those are different payment structures and billing periods. Confirm the next renewal date and shipment schedule; a 12-month plan description alone does not establish how much medication arrives in each package.

Sources: [6]

Which pharmacy will prepare my medication?

The public documentation does not assign each product to a named pharmacy. The terms list Foothills Pharmacy and Promise Pharmacy, while the homepage says patients may specify another licensed pharmacy. Ask for the actual dispensing and preparing pharmacy, full formulation, route, presentation and any effect of pharmacy choice on the quoted bundle before treating the advertised price as a complete product description.

Sources: [9] [6]

How do I contact someone about side effects?

Sprout directs medical questions to the licensed clinician through the patient account or medical portal; its administrative team cannot give medical advice. Orders from July 2026 onward use the patient-account pathway, while earlier orders have a Customer Portal. The consulted pages do not specify a clinical response-time guarantee, so clarify how time-sensitive concerns are handled before relying on portal messaging.

Sources: [10]

Can I cancel after the prescription reaches the pharmacy?

You can request cancellation of future service, but that does not establish a refund for the current order. The policy calls orders nonrefundable after the prescription is sent for fulfillment, while separately describing refunds for unshipped months of prepaid plans. Ask how both provisions apply to your order. To avoid the next charge, the request must arrive at least 48 hours before billing.

Sources: [8]

Does Sprout serve California or every other state?

The consulted pages do not resolve that reliably. The terms exclude California and five other states, while the privacy policy claims all-state availability. Arkansas appears both in the exclusions and in the synchronous-visit list. These inconsistencies do not prove that a particular service is unavailable, but they make written confirmation of state and treatment access important before enrollment.

Sources: [9] [7]

Our assessment

Sprout’s documentation has useful strengths: explicit compounded-drug disclosures, visible prices, a clinician-controlled prescribing model and detailed refund and delivery rules. Those are meaningful service disclosures, not proof of treatment effectiveness. The main weaknesses are missing product specifics and inconsistent descriptions of billing, geography, privacy and reporting windows. A practical next step is to obtain the exact formulation, pharmacy, checkout schedule, applicable cancellation terms and clinical contact pathway in writing. Sprout is documented as a GLP-1 coordination service, but the available record does not justify treating its compounded offerings as clinically validated by trials of other products or its operational claims as independently verified.

Visit Sprout Health’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Sprout Health Review: What Its GLP-1 Documentation Establishes—and What It Does Not

At a glance

01Start with the product evidence, not the ingredient name

02What published research can—and cannot—add

03Who reviews the patient—and who coordinates the service

04Prices are concrete; the billing calendar is less consistent

05Pharmacy handoffs and follow-up need separate scrutiny

06Cancellation and refunds turn on different events

07Delivery complaints have short, unevenly described deadlines

08State coverage and privacy remain unresolved